What is HC Wainwright's Estimate for RLAY FY2027 Earnings?

Key Points

• HC Wainwright estimates Relay Therapeutics will report FY2027 EPS of ($1.60), matching the current consensus estimate. The firm maintains a “Buy” rating and a $29.00 price target.
• Relay Therapeutics recently reported quarterly EPS of ($0.41), missing the ($0.39) analyst consensus, while revenue of $0.35 million fell short of the $0.96 million estimate.
• The stock opened at $19.70 after declining 5.0%; analysts maintain an overall “Moderate Buy” consensus rating with an average price target of $25.92.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Relay Therapeutics in a research note issued on Thursday, August 20th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($1.60) for the year. HC Wainwright currently has a "Buy" rating and a $29.00 target price on the stock. The consensus estimate for Relay Therapeutics' current full-year earnings is ($1.60) per share.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). The firm had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.96 million.

Several other equities analysts also recently commented on RLAY. Canaccord Genuity Group initiated coverage on shares of Relay Therapeutics in a report on Thursday, July 16th. They issued a "buy" rating and a $29.00 price objective on the stock. JonesTrading raised shares of Relay Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 19th. The Goldman Sachs Group upped their target price on Relay Therapeutics from $22.00 to $31.00 and gave the company a "buy" rating in a research report on Tuesday, July 21st. Wells Fargo & Company boosted their price target on Relay Therapeutics from $17.00 to $21.00 and gave the company an "overweight" rating in a research note on Tuesday, April 28th. Finally, Citizens Jmp boosted their target price on shares of Relay Therapeutics from $21.00 to $26.00 and gave the company a "market outperform" rating in a research report on Monday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $25.92.

Relay Therapeutics Trading Down 5.0%

Shares of NASDAQ RLAY opened at $19.70 on Friday. Relay Therapeutics has a 12 month low of $3.31 and a 12 month high of $21.27. The stock has a 50 day moving average of $18.77 and a 200-day moving average of $14.32. The company has a market capitalization of $4.32 billion, a P/E ratio of -12.55 and a beta of 1.69.

Hedge Funds Weigh In On Relay Therapeutics

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its position in shares of Relay Therapeutics by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 364,946 shares of the company's stock valued at $956,000 after purchasing an additional 38,812 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Relay Therapeutics by 6.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company's stock worth $221,000 after buying an additional 5,238 shares during the period. Millennium Management LLC increased its holdings in shares of Relay Therapeutics by 14.6% during the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company's stock valued at $7,710,000 after acquiring an additional 374,491 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Relay Therapeutics in the 1st quarter worth $53,000. Finally, Woodline Partners LP increased its position in shares of Relay Therapeutics by 448.4% during the first quarter. Woodline Partners LP now owns 1,518,561 shares of the company's stock worth $3,979,000 after acquiring an additional 1,241,657 shares in the last quarter. 96.98% of the stock is currently owned by institutional investors.

Insider Activity

In other Relay Therapeutics news, insider Peter Rahmer sold 50,000 shares of the business's stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total transaction of $954,500.00. Following the completion of the transaction, the insider owned 225,857 shares of the company's stock, valued at approximately $4,311,610.13. The trade was a 18.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sanjiv Patel sold 48,199 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $19.58, for a total transaction of $943,736.42. Following the completion of the transaction, the chief executive officer directly owned 615,898 shares of the company's stock, valued at approximately $12,059,282.84. The trade was a 7.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 409,639 shares of company stock valued at $7,233,399. 5.04% of the stock is owned by insiders.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source